Mounjaro cost: the list price, the $25 card, and the cash price that does not exist

There are three Mounjaro prices, and the one most people search for is the one that does not exist. There is a list price. There is a copay for the insured. There is no cash price, and understanding why explains most of what is confusing about paying for this drug.

The list price: $1,112.16 per fill

Lilly publishes it on its own pricing page: "The list price of Mounjaro is $1,112.16 per fill".¹ A fill is a month, four weekly pens. That is the wholesale acquisition cost, the number a pharmacy starts from when it bills someone with no coverage, and it is flat across doses, unlike Zepbound's.

Almost nobody pays it, and Lilly's own page is careful to say the amount you pay "will largely depend on your prescription drug insurance plan".¹ But it is the price behind every other number, and it is what you are looking at if you walk into a pharmacy uninsured with a Mounjaro prescription.

The insured price: as little as $25

For people with commercial insurance that covers Mounjaro, Lilly's card takes the copay down: "Eligible, commercially insured patients with Mounjaro coverage can pay as little as $25 for up to a 3-month prescription with the Mounjaro Savings Program."² Government plans are excluded, as with every manufacturer card.

The load-bearing word is coverage, and coverage follows the label. Mounjaro is approved "to improve blood sugar (glucose) in adults and children 10 years of age and older with type 2 diabetes mellitus", and to reduce cardiovascular risk in diabetic adults.² For those uses it is one of the most widely covered drugs in the country. Prescribed for weight loss it is refused almost everywhere, because it is not approved for that, and Lilly's site says so in bold: "Mounjaro is not a weight loss drug."² Here is where eight insurers stand, in their own words:

Every one of them says no to Mounjaro for weight. If you have type 2 diabetes, the $25 route is open. If you do not, the card is not your route, and the savings card guide explains the programme's caps and why Zepbound's card is structured differently.

The cash price: there is not one

This is the part that separates Mounjaro from every other drug in the category. Lilly sells Zepbound direct to cash patients at published prices: $299, $399, $499 and $699 a month by dose, as a vial or KwikPen, through a programme it describes as "the price at which Lilly sells the product directly to patients".³ Zepbound is tirzepatide. Mounjaro is tirzepatide. The same molecule at the same six doses.

For Mounjaro, Lilly's pricing page offers this: people whose insurance does not cover it, or who have none, "may be eligible for self-pay savings options. Terms and conditions apply."¹ No number. No programme name. No price to plan around. The direct-to-patient route exists for the weight-loss box and not for the diabetes box, and that is a commercial decision, not an accident.

What that means in dollars over a year

The gap between the first row and the third is the whole story of this drug's pricing. Coverage is not a discount on Mounjaro; it is the difference between $300 and $13,000 a year.

The third route: compounded tirzepatide

Because Mounjaro is tirzepatide, the cheap route is tirzepatide too. Licensed compounding pharmacies sell it through telehealth programs at prices that make even Zepbound's $699 look like a list price. Not FDA-approved as a finished product, which means no FDA review of the specific preparation for safety, effectiveness or quality, with the pharmacy's licensing in its place. From every seller we track, verified on their own pages today:

From $119 a month. Before choosing that route, check the seller; the price gap attracts the wrong pharmacies as well as the right ones.

What Mounjaro actually does for weight

Since most people asking about its cost are asking because of weight, the honest number from Lilly's own diabetes trials: weight loss in adults "ranged from 12 lb (5 mg) to 25 lb (15 mg)".² That is in people with type 2 diabetes, who lose less on these drugs than people without it. The same molecule in non-diabetic adults, in the Zepbound trials, produced 20.2% of body weight at 72 weeks in the only head-to-head; the tirzepatide vs semaglutide guide has the trial.

The honest summary

Mounjaro costs $1,112.16 a month at list, $25 a month with commercial coverage for diabetes, and an unpublished amount if you are paying cash, because Lilly reserves its direct-pay programme for the Zepbound box. If you have diabetes and coverage, it is among the cheapest drugs on this site to be on. If you are paying cash, it is the one drug in the category with no honest answer to "how much", and the answer is to buy the same molecule under a different name.